Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Continuous subcutaneous terbutaline infusion for treatment of preterm labor. Lansdale: HAYES, Inc.. Directory Publication. 2011 Authors' conclusions Terbutaline is used for the prevention of preterm birth. Typically, treatment for women with preterm uterine contractions is started with intensive tocolytic therapy. When contractions have been reduced to fewer than 4 to 6 per hour, terbutaline is administered as a continuous subcutaneous infusion to prevent the reinstatement of premature labor and preterm birth. Depending on the treatment protocol, terbutaline is infused with a pump at 0.05 mg to 0.75 mg per hour with boluses of 0.25 mg at regular intervals or as needed. Average duration of infusion ranges from 4 weeks to 7 weeks; however, some patients may require more than 10 weeks of infusion. Indexing Status Subject indexing assigned by CRD MeSH Humans; Infusions, Subcutaneous; Obstetric Labor, Premature; Pregnancy; Terbutaline Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32011001323 Date abstract record published 05/10/2011 |